PER
Click for more information
2.41% 8.1¢ percheron therapeutics limited

Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech? Health, page-384

  1. Ras.putin
    2 Posts.
    clock Created with Sketch.
    18/10/18
    16:49
    Post #: 36176125
    I like your posts, Mcexplorer!

    I remember you said on the BIT forum (at least I THINK it was you) that 0.11 was a good entry point and you bought at that price after it fell from 0.15 then. And when it fell to the 8s you got called out and look where BIT rocketed to.

    Thanks for your posts, really enjoy them. Keep them coming!
    ANP Price at posting: 5.1¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 7  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
HCH Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant
right-arrow Created with Sketch.
OBM Ora Banda sees FY26 gold output jumping to 150Koz/pa following key approval for Sand King
right-arrow Created with Sketch.
ENR Encounter Resources flags latest niobium hits in fresh assay data
right-arrow Created with Sketch.
TX3 Canadian fieldwork yields multiple pegmatites for Trinex
right-arrow Created with Sketch.
NEWS Hillcrest Energy Unveils Power Factor Correction Prototype to Meet Growing Demand
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.1¢ 		Change
-0.002(2.41%) 		Mkt cap ! $73.02M
Open High Low Value Volume
8.1¢ 8.2¢ 8.0¢ $39.27K 485.4K

Buyers (Bids)

No. Vol. Price($)
1 365000 8.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.4¢ 57142 1
View Market Depth
Last trade - 14.51pm 11/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.